Vitiligo Skin Punch Biopsy

Vitiligo Skin Punch Biopsy for Autoimmune Depigmentation Research

Vitiligo Skin Punch Biopsy samples are collected from IRB-consented donors with a clinically confirmed diagnosis of vitiligo. Biopsies are taken by licensed clinicians under aseptic conditions and, where frozen material is requested, are frozen within 4 hours of collection. Lesional depigmented, perilesional, and clinically normal non-lesional sites can be requested. These specimens support histological, immunological, and molecular research into melanocyte loss and the immune response that causes it.

Why Skin Tissue for Vitiligo Research

Vitiligo is an autoimmune disease in which epidermal melanocytes are destroyed by autoreactive cytotoxic T cells recognising melanocyte differentiation antigens. Both the target cell and the effector cells reside in the epidermis, so skin tissue is the only specimen in which the disease process itself can be observed.

• Melanocyte loss is defined histologically: lesional epidermis shows absence of melanocytes on immunostaining for markers such as Melan-A, SOX10, or MITF, and absence of melanin pigment. This is the primary endpoint for repigmentation research.
• CD8+ cytotoxic T cells accumulate at the advancing lesional margin, which is why perilesional biopsies are taken separately from stable depigmented centres — the two sites report on different phases of the disease.
• The IFN-gamma–CXCL9/CXCL10–CXCR3 axis recruits autoreactive T cells into the epidermis, and these chemokines are measurable in lesional tissue. Signalling downstream of IFN-gamma runs through JAK-STAT, which is the mechanistic basis for JAK inhibitor therapy in vitiligo.
• Autoreactive resident memory CD8+ T cells persist in lesional and in clinically normal-appearing skin and are implicated in relapse after treatment withdrawal; these cells are recoverable only from tissue, not from blood.
• Melanocyte-intrinsic oxidative and cellular stress responses contribute to susceptibility, and these are assessed in the melanocyte and keratinocyte compartments in situ.
• Paired lesional and non-lesional biopsies from the same donor provide an internally controlled comparison, separating disease-driven change from inter-individual and skin-type variation.

Donor Stratification Available

• Subtype: nonsegmental (generalised or acrofacial), segmental, or universal vitiligo
• Disease activity: stable versus actively spreading, including confetti-like depigmentation, trichrome lesions, or Koebner phenomenon where documented
• Biopsy site: lesional depigmented centre, perilesional advancing margin, or clinically normal non-lesional skin
• Extent of involvement and body surface area or VASI score where recorded
• Treatment status: topical corticosteroid, topical calcineurin inhibitor, JAK inhibitor, narrowband UVB phototherapy, or treatment-naive
• Concurrent autoimmune conditions, notably autoimmune thyroid disease, and Fitzpatrick skin type
• Matched healthy controls available

Product Features

• Research Use Only (RUO), fresh or frozen skin punch biopsies
• Samples are frozen (if requested) within 4 hours of collection
• Clinically confirmed vitiligo donors
• Collected by licensed clinicians under aseptic conditions
• Lesional, perilesional, and non-lesional sites available from the same donor on request
• Processed and shipped same-day where applicable
• IRB-approved protocols and electronic informed consent

De-identified Donor Data

• Verified diagnosis of vitiligo and subtype where documented
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and lesion site
• Disease activity, extent, and clinical history available upon request

Applications

• Immunohistochemical quantification of melanocyte density and pigment loss
• Multiplex imaging of CD8+ T cell infiltrates at the lesional margin
• Characterisation of resident memory T cell populations in lesional and non-lesional skin
• Measurement of IFN-gamma-inducible chemokines and JAK-STAT pathway activation in situ
• Spatial and single-cell transcriptomic profiling of epidermal and dermal compartments
• Target validation for JAK inhibitor, IL-15, and CXCR3-directed therapeutic programmes
• Melanocyte stress response and oxidative damage studies
• Repigmentation and melanocyte regeneration research, including follicular melanocyte reservoirs

Other Vitiligo Specimen Types

• Vitiligo Serum
• Vitiligo Plasma
• Vitiligo Whole Blood
• Vitiligo PBMC
• Vitiligo Leukopak

Compliance and Quality Assurance

• IRB-approved collections and SOP-driven processing
• 21 CFR Part 11-compliant electronic informed consent
• HIPAA-compliant donor data management

Ordering & Customization

Vitiligo Skin Punch Biopsy samples can be shipped ambient, refrigerated, or on dry ice. For pricing, availability, orders outside the United States, or regulatory documentation, please contact learnmore@sanguinebio.com. To browse other disease states and biopsy formats, visit our human skin punch biopsy page.